D.J. St. Germain’s Regeneron Pharmaceuticals REGN Stock Holding History

D.J. St. Germain’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22	Closed	-$14K	–	936
2025 Q1	$14K	Buy	+22	New	+$15.1K	﹤0.01%	534
2020 Q3	–	Sell	-471	Closed	-$294K	–	220
2020 Q2	$294K	Buy	471 +6	+1%	+$3.41K	0.03%	183
2020 Q1	$227K	Buy	+465	New	+$192K	0.02%	193

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.J. St. Germain's REGN Position: Q2 2025 in Review

D.J. St. Germain sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 22 shares — an estimated $14K sold.

D.J. St. Germain first reported a position in REGN in Q1 2020 and held it in 3 quarters. The position peaked at $294K in Q2 2020. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

D.J. St. Germain reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
D.J. St. Germain sold 22 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $14K.
D.J. St. Germain first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 3 quarters.
D.J. St. Germain's Regeneron Pharmaceuticals position peaked at $294K in Q2 2020.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on D.J. St. Germain's 13F filing for Q2 2025, filed 16 Jul 2025.